factor IX


Also found in: Dictionary, Thesaurus, Legal, Financial, Encyclopedia, Wikipedia.
Related to factor IX: factor XI

factor

 [fak´ter]
an agent or element that contributes to the production of a result.
accelerator factor factor V, one of the coagulation factors.
factor I see coagulation factors.
factor II see coagulation factors.
factor III see coagulation factors.
factor IV see coagulation factors.
factor V see coagulation factors.
factor VI see coagulation factors.
factor VII see coagulation factors.
factor VIII see coagulation factors.
factor IX see coagulation factors.
factor X see coagulation factors.
factor XI see coagulation factors.
factor XII see coagulation factors.
factor XIII see coagulation factors.
angiogenesis factor a substance that causes the growth of new blood vessels, found in tissues with high metabolic requirements such as cancers and the retina. It is also released by hypoxic macrophages at the edges or outer surface of a wound and initiates revascularization in wound healing.
antihemophilic factor (AHF)
2. a preparation of factor VIII administered intravenously for the prevention or treatment of hemorrhage in patients with hemophilia A and the treatment of von Willebrand disease, hypofibrinogenemia, and coagulation factor XIII deficiency. Included are preparations derived from human plasma (antihemophilic factor, cryoprecipitated antihemophilic factor) or porcine plasma (antihemophilic factor [porcine]) and those produced by recombinant technology antihemophilic factor [recombinant]).
antihemophilic factor A factor VIII, one of the coagulation factors.
antihemophilic factor B factor IX, one of the coagulation factors.
antihemophilic factor C factor XI, one of the coagulation factors.
antihemorrhagic factor vitamin K.
antinuclear factor (ANF) antinuclear antibody.
antirachitic factor vitamin D.
atrial natriuretic factor (ANF) a hormone produced in the cardiac atrium; an inhibitor of renin secretion and thus of the production of angiotensin, and a stimulator of aldosterone release. Its effect is increased excretion of water and sodium and a lowering of blood pressure.
factor B a complement component that participates in the alternative complement pathway.
blastogenic factor lymphocyte-transforming factor.
carative f's in the theory of human caring, a set of ten factors that offer a descriptive topology of interventions including (1) a humanistic-altruistic system of values; (2) faith-hope; (3) sensitivity to self and others; (4) a helping-trusting, human care relationship; (5) the expression of positive and negative feelings; (6) a creative problem-solving caring process; (7) transpersonal teaching and learning; (8) a supportive, protective, and/or corrective mental, physical, societal, and spiritual environment; (9) human needs assistance; and (10) existential-phenomenological-spiritual forces.
Christmas factor factor IX, one of the coagulation factors.
citrovorum factor folinic acid.
clotting f's coagulation factors.
C3 nephritic factor (C3 NeF) an autoantibody that stabilizes the alternative complement pathway C3 convertase, preventing its inactivation by factor h, resulting in complete consumption of plasma C3; it is found in the serum of many patients with type II membranoproliferative glomerulonephritis.
coagulation f's see coagulation factors.
colony-stimulating factor (CSF) any of a number of glycoproteins responsible for the proliferation, differentiation, and functional activation of hematopoietic progenitor cells; specific factors are named for the cell lines that they stimulate. Used to promote bone marrow proliferation in aplastic anemia, following cytotoxic chemotherapy, or following bone marrow transplantation. Types include granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors.
factor D a factor that when activated serves as a serine esterase in the alternative complement pathway.
decay accelerating factor (DAF) a protein of most blood as well as endothelial and epithelial cells, CD55 (see CD antigen); it protects the cell membranes from attack by autologous complement.
endothelial-derived relaxant factor (endothelial-derived relaxing factor) (endothelium-derived relaxing factor (EDRF)) nitric oxide.
extrinsic factor cyanocobalamin.
F factor (fertility factor) F plasmid.
fibrin-stabilizing factor (FSF) factor XIII, one of the coagulation factors.
Fletcher factor prekallikrein.
granulocyte colony-stimulating factor (G-CSF) a colony-stimulating factor that stimulates production of neutrophils from precursor cells.
granulocyte-macrophage colony-stimulating factor (GM-CSF) a colony-stimulating factor that binds to stem cells and most myelocytes and stimulates their differentiation into granulocytes and macrophages.
growth factor any substance that promotes skeletal or somatic growth; usually a mineral, hormone, or vitamin.
factor H a complement system regulatory protein that inhibits the alternative pathway of complement activation.
Hageman factor (HF) factor XII, one of the coagulation factors. See illustration.
Activation of Hageman factor (factor XII) leads to increased vascular permeability, clotting, and thrombolysis. From Damjanov, 2000.
hematopoietic growth f's a group of substances with the ability to support hematopoietic colony formation in vitro, including erythropoietin, interleukin-3, and colony-stimulating factors. All except erythropoietin stimulate mature cells, have overlapping capabilities to affect progenitor cells of several blood cell lines, and also affect cells outside the hematopoietic system.
histamine-releasing factor (HRF) a lymphokine, believed to be produced by macrophages and B lymphocytes, that induces the release of histamine by IgE-bound basophils. It occurs in late phase allergic reaction, six or more hours after contact with the antigen, in sensitive individuals.
homologous restriction factor (HRF) a regulatory protein that binds to the membrane attack complex in autologous cells, inhibiting the final stages of complement activation.
factor I a plasma enzyme that regulates both classical and alternative pathways of complement activation by inactivating their C3 convertases.
immunoglobulin-binding factor (IBF) a lymphokine having the ability to bind IgG complexed with antigen and prevent complement activation.
insulinlike growth f's (IGF) insulinlike substances in serum that do not react with insulin antibodies; they are growth hormone–dependent and possess all the growth-promoting properties of the somatomedins.
intensification factor in radiology, the comparative increase in light transmission when films are exposed in the presence of intensifying screens compared to that in the absence of screens.
intrinsic factor a glycoprotein secreted by the parietal cells of the gastric glands, necessary for the absorption of cyanocobalamin (vitamin B12). Its absence results in pernicious anemia.
LE factor an immunoglobulin that reacts with leukocyte nuclei, found in the serum in systemic lupus erythematosus.
lymph node permeability factor (LNPF) a substance from normal lymph nodes that produces vascular permeability.
lymphocyte mitogenic factor (LMF) (lymphocyte-transforming factor) a substance that is released by lymphocytes stimulated by specific antigen and causes nonstimulated lymphocytes to undergo blast transformation and cell division; called also blastogenic factor.
macrophage-activating factor (MAF) interferon-α.
macrophage colony-stimulating factor (M-CSF) a colony-stimulating factor secreted by macrophages, stimulated endothelial cells, and most tissues, that stimulates the production of macrophages from precursor cells and maintains the viability of mature macrophages in vitro.
macrophage chemotactic factor (MCF) a lymphokine that attracts macrophages to the invasion site.
macrophage-derived growth factor a substance released by macrophages below the surface of a wound that induces the proliferation of fibroblasts.
macrophage inhibition factor (macrophage inhibitory factor) migration inhibitory factor.
migration inhibition factor (migration inhibitory factor) a lymphokine that inhibits macrophage migration.
minification factor in radiology, the gain in light achieved by a reduction in size of the output phosphor from the input phosphor size.
osteoclast-activating factor (OAF) a lymphokine that stimulates bone resorption; it may be involved in the bone resorption associated with multiple myeloma and other hematologic neoplasms or inflammatory disorders such as rheumatoid arthritis and periodontal disease.
factor P properdin.
platelet f's see platelet factors.
platelet-activating factor (PAF) a substance released by basophils and mast cells in immediate hypersensitivity reactions, and by macrophages and neutrophils in other inflammatory reactions; it leads to bronchoconstriction, platelet aggregation, and release of vasoactive substances from platelets.
platelet-derived growth factor a substance contained in platelets and capable of inducing proliferation of vascular endothelial cells, vascular smooth muscle cells, fibroblasts, and glial cells; its action contributes to the repair of damaged vascular walls.
R factor R plasmid.
releasing f's factors elaborated in one structure (as in the hypothalamus) that effect the release of hormones from another structure (as from the anterior pituitary gland), including corticotropin-releasing factor, melanocyte-stimulating hormone–releasing factor, and prolactin-releasing factor. Applied to substances of unknown chemical structure, while substances of established chemical identity are called releasing hormones.
resistance factor R f.
Rh factor a type of agglutinogen found on some erythrocytes; see also rh factor.
rheumatoid factor (RF) antibodies directed against antigenic determinants on IgG molecules, found in the serum of about 80 per cent of patients with classic or definite rheumatoid arthritis; but in only about 20 per cent of patients with juvenile rheumatoid arthritis; rheumatoid factors may be IgM, IgG, or IgA antibodies, although serologic tests measure only IgM. Rheumatoid factors also occur in other connective tissue diseases and infectious diseases.
risk factor an agent or situation that is known to make an individual or population more susceptible to the development of a specific negative condition.
risk factor (omaha) an environmental, psychosocial, or physiologic event or health related behavior that increases the client's exposure or vulnerability to the development of a client problem; the nurse's knowledge base of risk factors is used to identify potential problem modifiers in the Problem Classification scheme of the omaha system.
stable factor factor VII, one of the coagulation factors.
Stuart factor (Stuart-Prower factor) factor X, one of the coagulation factors.
sun protection factor (SPF) a numerical rating of the amount of protection afforded by a sunscreen; the higher the number, the more protection is provided.
tissue factor factor III, one of the coagulation factors.
transfer factor (TF) a factor occurring in sensitized lymphocytes that can transfer delayed hypersensitivity to a formerly nonreactive individual; see also transfer factor.
tumor necrosis factor (TNF) either of two lymphokines produced primarily by cells of the immune system, capable of causing in vivo hemorrhagic necrosis of certain tumor cells but not normal cells. They also destroy cells associated with the inflammatory response. They have been used as experimental anticancer agents but can also induce shock when bacterial endotoxins cause their release. Tumor necrosis factor α, formerly called cachectin, contains 157 amino acids and is produced by macrophages, eosinophils, and NK cells. Tumor necrosis factor β is lymphotoxin and contains 171 amino acids.
vascular endothelial growth factor (VEGF) (vascular permeability factor (VPF)) a peptide factor that stimulates the proliferation of cells of the endothelium of blood vessels; it promotes tissue vascularization and is important in blood vessel formation in tumors.
von Willebrand's factor (vWF) a glycoprotein synthesized in endothelial cells and megakaryocytes that circulates complexed to coagulation factor VIII. It is involved in adhesion of platelets to damaged epithelial surfaces and may participate in platelet aggregation. Deficiency results in the prolonged bleeding time seen in von Willebrand's disease.

fac·tor IX

in the clotting of blood, also known as: Christmas factor (Biggs and Macfarlane), plasma thromboplastin component (Aggeler), antihemophilic globulin B (Cramer), plasma thromboplastin factor B (Aggeler), plasma factor X (Shulman), antihemophilic factor B, and platelet cofactor II. Factor IX is required for the formation of intrinsic blood thromboplastin and affects the amount formed (rather than the rate). Its active form, factor IXa (EC 3.4.21.22) is a serine proteinase converting factor X to factor Xa by cleaving an arginine-isoleucine bond. Deficiency of factor IX causes hemophilia B.

factor IX

n.
A protein substance in blood plasma that is essential for the clotting of blood. A deficiency of this factor is the cause of Christmas disease.

factor IX

a serine protease coagulation factor present in normal plasma but deficient from the blood of persons with hemophilia B. Factor IX forms a complex with its cofactor, factor VIII to activate factor X. Also called Christmas factor.

factor IX

Christmas factor, coagulation factor IX Hematology An intrinsic pathway factor which, when activated–IXa, combines with Factor VIII and a phospholipid to activate Factor X in the common pathway. See Common pathway, Factor IX deficiency.

fac·tor IX

(fak'tŏr)
In the clotting of blood, required for the formation of intrinsic blood thromboplastin; deficiency causes hemophilia B.
Synonym(s): antihemophilic globulin B, Christmas factor, plasma thromboplastin component.

factor IX

One of the many factors necessary for blood clotting. Absence of factor IX occurs as a result of an X-LINKED gene mutation and causes Christmas disease, a form of HAEMOPHILIA almost identical to factor VIII deficiency haemophilia. The drug is on the WHO official list. Human coagulation Factor IX is produced in freeze-dried form derived from donated blood under the brand names Mononine and Replenine.

fac·tor IX

(fak'tŏr)
In blood clotting, also known as: Christmas factor and other designations; required for formation of intrinsic blood thromboplastin and affects the amount formed (rather than the rate).
References in periodicals archive ?
He believes that the amount of factor IX produced would rise if the team could deliver more of the viral vectors to the dog liver cells.
Hemophilia B occurs in about one in 25,000 male births annually and is caused by having substantially reduced or no Factor IX protein, which is needed for normal blood clotting.
About Hemophilia B Hemophilia B (congenital factor IX deficiency) is characterized by deficient or defective factor IX and affects approximately 1 in 25,000 to 50,000 people.
The lead candidates in its pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and the GlycoPEGylated hemostasis compounds Factor VIIa, Factor VIII, and Factor IX, target markets with aggregate 2006 sales of approximately $8 billion.
ProGenetics has developed production of recombinant human factor IX in the milk of transgenic pigs.
Spark's development program for hemophilia B, SPK-FIX, is advancing proprietary, bio-engineered adeno-associated virus (AAV) vectors that deliver a high-activity Factor IX gene to the liver.
We are very pleased to work with ProGenetics to add factor IX, factor VIII, and fibrinogen to our portfolio of recombinant coagulation factors," stated Geoffrey F.
Jude Children's Research Hospital, University College London (UCL) and the Royal Free Hospital has transformed life for men with a severe form of hemophilia B by providing a safe, reliable source of the blood clotting protein Factor IX that has allowed some to adopt a more active lifestyle, researchers reported.
Contract notice: Tender for the Supply of Recommbinant Antihaemophilia Factor IX.
Cook Pharmica, the contract biopharmaceutical manufacturing and development services division of Cook Medical, announced today that it has signed an agreement with Inspiration Biopharmaceuticals, to conduct development work for its lead biologic therapy, an intravenous Factor IX product for patients with hemophilia B.
Contract award: the concentrate of clotting factor ix and recombinant osoczopochodny delivered to the patient~s home / to the haemophilia center.
MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and III findings presented today by CSL Behring at the World Federation of Hemophilia (WFH) 2014 Congress demonstrate an improved pharmacokinetic (PK) profile of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) among hemophilia B patients of all age groups.